Guard Therapeutics International AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was SEK 40.49 million compared to SEK 22.71 million a year ago. Basic loss per share from continuing operations was SEK 5.5 compared to SEK 4.5 a year ago.
For the full year, net loss was SEK 112.84 million compared to SEK 82.03 million a year ago. Basic loss per share from continuing operations was SEK 16 compared to SEK 18.5 a year ago.